93 related articles for article (PubMed ID: 12185379)
21. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
[TBL] [Abstract][Full Text] [Related]
22. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
[TBL] [Abstract][Full Text] [Related]
23. Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment.
Leonhardt W; Hanefeld M; Fischer S; Schulze J; Spengler M
Arzneimittelforschung; 1991 Jul; 41(7):735-8. PubMed ID: 1772463
[TBL] [Abstract][Full Text] [Related]
24. [The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees and the response of AIP to Acarbose or Glimepiride in therapy of type 2 diabetes mellitus].
Yang B; Tian H; Ren Y; Tong N; Yu H; Han L; Ran X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Jun; 22(3):560-4. PubMed ID: 16013260
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.
Wagner H; Degerblad M; Thorell A; Nygren J; Ståhle A; Kuhl J; Brismar TB; Ohrvik J; Efendic S; Båvenholm PN
Diabetes Care; 2006 Jul; 29(7):1471-7. PubMed ID: 16801564
[TBL] [Abstract][Full Text] [Related]
26. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
[TBL] [Abstract][Full Text] [Related]
27. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Fogari E; Salvadeo SA; Ferrari I; Gravina A; Fassi R; Fogari R
Clin Drug Investig; 2006; 26(9):529-39. PubMed ID: 17163286
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.
de Rivas B; Luque M; Martell N; Fernández C; Fernández-Cruz A
J Clin Hypertens (Greenwich); 2007 Jul; 9(7):530-7. PubMed ID: 17617763
[TBL] [Abstract][Full Text] [Related]
29. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
30. RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.
Derosa G; Maffioli P; D'Angelo A; Fogari E; Bianchi L; Cicero AF
J Diabetes Complications; 2011; 25(4):258-66. PubMed ID: 21367625
[TBL] [Abstract][Full Text] [Related]
31. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study.
Hwu CM; Ho LT; Fuh MM; Siu SC; Sutanegara D; Piliang S; Chan JC;
Diabetes Res Clin Pract; 2003 May; 60(2):111-8. PubMed ID: 12706319
[TBL] [Abstract][Full Text] [Related]
32. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
[TBL] [Abstract][Full Text] [Related]
33. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.
Salman S; Salman F; Satman I; Yilmaz Y; Ozer E; Sengül A; Demirel HO; Karşidağ K; Dinççağ N; Yilmaz MT
Curr Med Res Opin; 2001; 16(4):296-306. PubMed ID: 11268714
[TBL] [Abstract][Full Text] [Related]
34. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
35. Acarbose and nutrient intake in non-insulin dependent diabetes mellitus.
Tuomilehto J; Pohjola M; Lindström J; Aro A
Diabetes Res Clin Pract; 1994 Dec; 26(3):215-22. PubMed ID: 7736902
[TBL] [Abstract][Full Text] [Related]
36. Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.
Lindström J; Tuomilehto J; Spengler M
Diabet Med; 2000 Jan; 17(1):20-5. PubMed ID: 10691155
[TBL] [Abstract][Full Text] [Related]
37. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
38. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients.
Delgado H; Lehmann T; Bobbioni-Harsch E; Ybarra J; Golay A
Diabetes Metab; 2002 Jun; 28(3):195-200. PubMed ID: 12149599
[TBL] [Abstract][Full Text] [Related]
39. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus.
Rodier M; Richard JL; Monnier L; Mirouze J
Diabete Metab; 1988; 14(1):12-4. PubMed ID: 3292303
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
Leonhardt W; Hanefeld M; Fischer S; Schulze J
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():45-9. PubMed ID: 8001628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
